Primary hyperparathyroidism is an underdiagnosed disease, and many patients can benefit from surgery that is both highly effective and very safe.
This primary message will be explored during Sunday morning’s panel discussion on “The Mystery of the Hidden Parathyroid Adenoma.” The session begins at 8:45 am Sunday in Panzacola F/G.
“Primary hyperparathyroidism remains an under-diagnosed disease. Treatment of this condition is of benefit to many patients, even if they are asymptomatic,” said session moderator Jennifer L. Marti, MD, FACS, who is Assistant Professor of Surgery, Endocrine & Breast Surgical Oncology, at Mount Sinai Beth Israel in New York. “Many patients may be undergoing monitoring and experiencing progression of disease, most of whom can be expeditiously cured with minimally invasive surgery.”
The panel, which will also include Azeez Farooki, MD, Associate Attending Physician in the Endocrinology Service at Memorial Sloan Kettering Cancer Center and Associate Clinical Professor at Weill Cornell Medical College in New York, and Peter M. Sadow, MD, PhD, Associate Professor of Pathology at Harvard Medical School, and Associate Director of Head & Neck Pathology at Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary, will help attendees unravel the complexities in the diagnosis, workup and management of patients with primary hyperparathyroidism.
“Dr. Farooki will help clarify some of the complexities in the diagnosis of the disease and long-term sequelae of patients who do not undergo surgery,” said Dr. Marti. “Dr. Sadow will discuss some of the tools pathologists use to guide intraoperative decision making.”
Newer parathyroid imaging modalities such as 4DCT will be included in the discussion.
“The vast majority of patients, even those with ‘borderline’ disease, benefit from consultation with both an endocrinologist and an endocrine surgeon. An experienced parathyroid surgeon is uniquely positioned to explain both the risks and benefits of parathyroid surgery,” said Dr. Marti.